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Abstract The protein RPE65 has an important role in retinoid
processing and/or retinoid transport in the eye. Retinoids are
involved in cell differentiation, embryogenesis and carcinogen-
esis. Since the kidney is known as an important site for retinoid
metabolism, the expression of RPE65 in normal kidney and
transformed kidney cells has been examined. The RPE65 mRNA
was detected in transformed kidney cell lines including the human
embryonic kidney cell line HEK293 and the African green
monkey kidney cell lines COS-1 and COS-7 by reverse
transcription PCR. In contrast, it was not detected in human
primary kidney cells or monkey kidney tissues under the same
PCR conditions. The RPE65 protein was also identified in
COS-7 and HEK293 cells by Western blot analysis using a
monoclonal antibody to RPE65, but not in the primary kidney
cells or kidney tissues. The RPE65 cDNA containing the full-
length encoding region was amplified from HEK293 and COS-7
cells. DNA sequencing showed that the RPE65 cDNA from
HEK293 cells is identical to the RPE65 cDNA from the human
retinal pigment epithelium. The RPE65 from COS-7 cells shares
98 and 99% sequence identity with human RPE65 at the
nucleotide and amino acid levels, respectively. Moreover, the
RPE65 mRNA was detected in three out of four renal tumor
cultures analyzed including congenital mesoblastic nephroma
and clear cell sarcoma of the kidney. These results demonstrated
that transformed kidney cells express this retinoid processing
protein, suggesting that these transformed cells may have an
alternative retinoid metabolism not present in normal kidney
cells.
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1. Introduction
RPE65 (p63) was identi¢ed and puri¢ed from the retinal
pigment epithelium (RPE) [1,2]. It was originally reported to
be speci¢cally expressed in the RPE, preferentially in the mi-
crosomal fraction. It has been reported that RPE65 associates
with the plasma retinol-binding protein (RBP) and thus, it
was proposed to be the RBP receptor in the RPE [1,3]. It is
known that the RPE is an important site for retinoid metab-
olism in the vision process [4^9] and RPE65 forms a complex
with 11-cis retinal dehydrogenase [10]. The RPE65 knockout
mouse model has an abnormal rhodopsin generation in the
retina and disturbed retinoid pro¢le in the RPE, suggesting a
disrupted retinoid processing [11]. Recently, a number of mu-
tations in the RPE65 gene have been shown to be linked to
Leber’s congenital amaurosis (LCA), autosomal recessive
childhood onset severe retinal dystrophies (arCSRDs) and
retinitis pigmentosa [12^14]. These ¢ndings suggest that
RPE65 may be involved in retinoid processing and that a
functional RPE65 is required for the physiological function
of the RPE and normal vision.
Retinoids play important roles in cell proliferation and dif-
ferentiation [15^17]. They also regulate animal development,
embryogenesis and carcinogenesis via regulating gene expres-
sion [17^19]. It has been suggested that some cancer cells have
altered retinoid processing and signaling pathways as they
have altered expression of retinoid receptors, binding proteins
and processing enzymes [20^24]. It has been shown that when
a mouse cell line was transformed by the bovine papilloma
virus, cellular retinoid acid-binding protein levels were mark-
edly increased [20]. In contrast, serum levels of RBP are sig-
ni¢cantly lower in patients with malignant tumors of the head
and neck region [25]. The altered retinoid metabolism may
contribute to carcinogenesis in tumor tissues.
The kidney is an important site for retinoid metabolism
[26^29]. RBP, a carrier transporting retinol to target tissues,
has been shown to be cleared from the circulation by the
kidney [29]. The kidney contains the highest retinal oxidase
activity and may play a major role in the oxidative metabo-
lism of retinol [26]. Retinoids have important functions in the
regulation of gene expression, embryogenesis and morphogen-
esis in the kidney [18,19,30,31]. Retinoic acid (RA), interact-
ing with growth factors, promotes tubulogenesis in cultured
adult renal proximal tubule cells in a manner reminiscent of
inductive embryonic kidney morphogenesis [31]. Retinoid X
receptor (RXR) is known to form a heterodimer with 1,25-
dihydroxyvitamin D3 (VD) receptor (VDR) and plays an im-
portant role in the VD-regulated transactivation in tubular
cells [32].
We have examined the expression of RPE65 in transformed
kidney cells, primary cultures of renal tumors and normal
kidney tissues and report here that the RPE65 is expressed
in transformed kidney cells, but not in normal kidney tis-
sue.
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2. Materials and methods
2.1. RNA isolation from cultures of kidney proximal tubular cells,
transformed kidney cells and renal tumors
Transformed kidney cell lines COS-1, COS-7 and HEK293 cells
were purchased from the American Type Culture Collection (Rock-
ville, MD, USA). Human renal cell cultures were derived from normal
kidney tissues (proximal tubular cell) and two pediatric renal neo-
plasms including congenital mesoblastic nephroma (CMN-1 and
CMN-2) and clear cell sarcoma of the kidney (CCSK-2 and CCSK-
BG1). Tumor cell lines were established, propagated and character-
ized by previously published procedures [33,34]. Total RNA was iso-
lated from kidney tissues and cells either by the guanidinium isothio-
cyanate-CsCl gradient centrifugation method [35] or the guanidinium
isothiocyanate-phenol/chloroform extraction method [36].
2.2. Reverse transcription (RT-) PCR and Southern blot analysis
The RT reaction mixture (20 Wl) contained 1 Wg total RNA,
100 pmol pd(N)6 random hexamer (Amersham Pharmacia Biotech,
Piscataway, NJ, USA), 4 Wl of 5U¢rst strand bu¡er (250 mM Tris-
HCl, pH 8.3, 375 mM KCl, 15 mM MgCl2), 2 Wl 0.1 M DTT, 3 Wl
2 mM dNTP and 10 U Moloney murine leukemia virus (M-MLV)
reverse transcriptase (Gibco BRL, Gaithersburg, MD, USA). The RT
mixture was incubated at 37‡C for 1 h followed by 95‡C for 5 min to
inactivate the reverse transcriptase. The RT products were used as
templates for PCR separately to amplify the RPE65 and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH). The PCR mixture in-
cluded 1 Wl of the RT products, 10 pmol of each primer, 2.5 Wl
10UPCR bu¡er (100 mM Tris-HCl, pH 8.3, 500 mM KCl, 15 mM
MgCl2, 0.1% gelatin), 3 Wl 2 mM dNTP, 2.5 U AmpliTaq (Perkin
Elmer Cetus, Foster City, CA, USA). For the RPE65 PCR, the 5P
primer had a sequence of 5P-GTTTCTGATTGTGGATCTC-3P and
the 3P primer was 5P-GGGATGTTAATCTCCACTTC-3P. For
GAPDH PCR, the 5P and 3P primers were 5P-GTGAACCATGAGA-
AG(A)TATGA-3P and 5P-TTGAAGTCAG(C)T(A)GGAGACAAC-
C-3P, respectively. The PCR was carried out for 30 cycles (94‡C,
1 min; 55‡C, 1 min and 72‡C, 3 min) in a Robocycler (Stratagene,
La Jolla, CA, USA). 5 Wl of each PCR product was probed with a
32P-labelled nested primer in a Southern blot analysis as described
previously [37].
2.3. Western blot analysis
COS-7, HEK293 and cultured primary human proximal tubular
cells and monkey kidney tissues were washed with PBS and homog-
enized in lysis bu¡er (50 mM Tris, pH 7.4, 150 mM NaCl, 0.5% NP-
40) containing protease inhibitors: 2 Wg/ml pepstatin, 2 WM E64,
0.5 mM PMSF and Protease Inhibitor Cocktail Tablets (Boehringer
Mannheim) 1 tablet/10 ml bu¡er. The cell debris were removed by
centrifugation at 14 000Ug at 4‡C for 10 min. The protein concen-
tration in the supernatant was measured with a Bio-Rad protein as-
say. 100 Wg of protein from each sample was loaded for a Western
blot analysis using the ECL (enhanced chemiluminescence) Western
blotting kit (Amersham International). Proteins were resolved with
SDS-PAGE (8^16% acrylamide gel) and then electrotransferred onto
a Hybond-ECL nitrocellulose membrane (Amersham International)
(25 V, 2 h). The membrane was blocked by incubation with 5% (w/
v) BLOTTO in TBST (20 mM Tris-Cl, pH 7.6, 137 mM NaCl, 0.1%
Tween 20) for 2 h at room temperature. The membrane was then
blotted with a monoclonal antibody speci¢c to bovine RPE65
(1:2000 dilution) (a generous gift from Dr John Saari at the Univer-
sity of Washington) overnight at 4‡C. The membrane was washed
three times with the BLOTTO solution, 15 min each, at room temper-
ature. A rabbit anti-mouse antibody labelled with horseradish peroxi-
dase (Amersham International) was diluted 1:10 000 in the BLOTTO
solution and incubated with the membrane for 3 h at room temper-
ature. The membrane was washed four times in TBST to remove free
antibody. Two detection solutions provided by the ECL kit were
mixed and added onto the surface of the membrane followed by
1 min incubation. The excess detection solution was drained o¡ and
the membrane was covered with SaranWrap and exposed to a Kodak
X-Omat ¢lm.
2.4. DNA sequence analysis
PCR products were puri¢ed by agarose gel electrophoresis and
sequenced on both strands by Sanger’s dideoxynucleotide chain ter-
mination method using the dsDNA Cycling Sequencing System (Gib-
co BRL). All sequences were veri¢ed by sequencing PCR products
from another independent PCR. The DNA sequence was analyzed by
the Wisconsin Genetics Computer Group (GCG) UNIX System. The
amino acid sequence was deduced using the GCG Translate program.
3. Results
3.1. Identi¢cation of RPE65 mRNA in transformed kidney cell
lines
Using primers speci¢c to the consensus sequences of the
human and bovine RPE65, RT-PCR ampli¢ed a single band
of RPE65 fragment from the transformed African green mon-
key kidney cell lines COS-1 and COS-7 and the transformed
human kidney cell line HEK293. The PCR products were
hybridized with a nested oligonucleotide probe speci¢c for
human RPE65 cDNA, which con¢rmed the speci¢city of the
PCR ampli¢cation (Fig. 1A). The PCR products showed an
expected length of 600 bp as estimated based on the human
and bovine RPE65 cDNA sequences. The size of 600 bp ex-
cluded that the PCR product was ampli¢ed from genomic
DNA, because the PCR primers span two large introns which
are more than 6 kb in length according to the human RPE65
gene [38]. Under the same PCR conditions, however, the
RPE65 mRNA was not detected in cultured primary kidney
proximal tubular cells or normal kidney tissue (Fig. 1A). Am-
pli¢cation of the house-keeping gene mRNA GAPDH was
used to assess the RNA integrity and e⁄ciency of reactions.
Using the same RT products as templates, a PCR of GAPDH
yielded comparable levels of products from all of the samples,
demonstrating that each reaction received an equal amount of
RNA (Fig. 1B). This indicated that the absence of RPE65 in
normal kidney cells and tissue was not a false negative result.
3.2. Identi¢cation of RPE65 protein in transformed kidney cell
lines
The presence of the RPE65 at the protein level was con-
¢rmed by Western blot analysis with a monoclonal antibody
speci¢c to RPE65. A single band of 65 kDa was recognized by
the monoclonal antibody in the RPE, COS-7 and HEK293
Fig. 1. RT-PCR and Southern blot analysis of RPE65 in trans-
formed kidney cell lines. RNAs from cells or tissues were used as
templates for RT-PCR using primers speci¢c to RPE65 (A) and
GAPDH (B) mRNA. The PCR products were subjected to South-
ern blot analysis using nested oligonucleotides as probes. A: PCR
ampli¢ed a speci¢c band of the RPE65 cDNA (600 bp) from COS-
1 (lane 1), COS-7 (lane 2) and HEK293 (lane 3) cells, but not from
primary human proximal tubular cells (lane 4) or monkey kidney
tissues (lane 5) under the same conditions. B: the PCR ampli¢ed a
GAPDH cDNA fragment (460 bp) from all the cells and tissues an-
alyzed.
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cells. However, no RPE65 was observed in the primary prox-
imal tubular cells or normal kidney tissue (Fig. 2). This result
demonstrated that RPE65 protein is also expressed in the
transformed kidney cells but not in the benign kidney tissue.
3.3. Sequence analysis of RPE65 from COS-7 and HEK293
cells
To determine whether the RPE65 mRNA in the trans-
formed kidney cells is from the legitimate RPE65 gene or
from another homologous gene, the full-length RPE65
cDNAs were synthesized from COS-7 and HEK293 cells.
The primers were designed according to the consensus se-
quence of the human and bovine RPE65 and span the full-
length encoding region. To exclude potential artefacts intro-
duced by PCR, PCR products from three independent PCRs
were puri¢ed and sequenced. The RPE65 ampli¢ed from
HEK293 cells showed an identical sequence to the human
RPE65 cDNA from the RPE while the RPE65 cDNA from
COS-7 cells did not match any existing sequences in the Gen-
Bank (Release 107.0, June 1998). The sequence from COS-7
cells is 1677 bp in length and contains a full-length open read-
Fig. 2. Western blot analysis of RPE65 in transformed kidney cells.
Western blot analysis was performed as described in Section 2. The
RPE65 monoclonal antibody recognizes a single band of 65 kDa in
the RPE (lane 1), COS-7 (lane 2) and HEK293 (lane 3) cells, but
not in the primary kidney cells (lane 4) or normal kidney tissue
(lane 5).
Fig. 3. Nucleotide and amino acid sequence of the RPE65 expressed in COS-7 cells. The lower line represents the nucleotide sequence and the
upper one is the deduced amino acid sequence. The stop codon is indicated by an asterisk. The potential glycosylation sites are in bold. This
sequence has been deposited into GenBank under accession number AF093455.
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ing frame. The translation start codon ATG is located at
position 40 in a Kozak context with an A at the 33 position
[39]. The stop codon is located at position 1639 (Fig. 3). The
cDNA encodes a protein of 533 residues and with a predicted
molecular weight of 60 991 and calculated pI of 6.35. Hydro-
pathy analysis indicates that it does not contain any typical
hydrophobic transmembrane helix. The deduced protein se-
quence contains three potential glycosylation sites (Asn-199,
Asn-282 and Asn-388) with the sequence of Asn-X-Ser/Thr
(Fig. 3).
A global GenBank search showed that the RPE65 cDNA
from COS-7 cells has a high sequence homology to the human
and bovine RPE65 isolated from the RPE. It shares 99 and
98% amino acid sequence identity to the human and bovine
RPE65, respectively. There are only two residues di¡erent
from that of human RPE65 (Fig. 4), indicating that RPE65
is highly conserved across species.
3.4. RPE65 mRNA in human renal tumor cells
In order to determine the expression of the RPE65 gene in
renal tumors, RNA from primary cultures of four renal tu-
mors was used for RT-PCR. Under the same conditions as
described above, the RPE65 mRNA was detected in three of
the four cultures analyzed, including a clear cell sarcoma
(CCSK-2) and two congenital mesoblastic nephromas
(CMN-1 and CMN-2). One case of clear cell sarcoma of the
kidney (CCSK-BG1) was devoid of RPE65 mRNA (Fig. 5A).
The speci¢city of PCR products was con¢rmed by Southern
blot analysis and DNA sequencing (Fig. 5A). The RPE65
mRNA was not detected in normal human kidney tissues or
cultured proximal tubular cells (Fig. 5A). However, the
GAPDH mRNA was detected in all of the samples at com-
parable levels (Fig. 5B), indicating that the lack of RPE65
Fig. 4. RPE65 cDNA sequence comparison between human, COS-7 cells, bovine and salamander RPE65. The deduced amino acid sequence of
the COS-7 RPE65 was aligned with the human, bovine and salamander (salam.) RPE65 using GCG (version 9.1). The human RPE65 is used
as the template and only the amino acids di¡erent from the human RPE65 are indicated in COS cells, bovine and salamander RPE65.
Fig. 5. RT-PCR and Southern blot analysis of RPE65 in renal tu-
mors. Total RNA from normal human kidney tissue and renal tu-
mors was used for RT-PCR and Southern blot analysis. A: PCR
ampli¢ed a 600 bp fragment of the RPE65 cDNA from a clear cell
sarcoma (CCSK-2) (lane 3) and two congenital mesoblastic nephro-
mas (CMN-1 and CMN-2) (lanes 4 and 5), but not from another
case of clear cell sarcoma (CCSK-BG1) (lane 6), normal human kid-
ney tissue (lane 1) or primary human proximal tubular cells (lane 2)
under the same conditions. B: PCR ampli¢ed a GAPDH cDNA
fragment (460 bp) from all the cells and tissues analyzed.
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mRNA in normal kidney tissues, proximal tubular cells and
CCSK-BG1 cells did not result from RNA degradation.
4. Discussion
RPE65, a protein originally found in the RPE, has been
suggested to play a role in the retinoid processing or transport
[1,40,41]. Recently, it was identi¢ed immunochemically in yolk
sac and was speculated to be responsible for the vitamin A
transport [42]. It was also identi¢ed in cone photoreceptor
cells but not in rods and thus, it may contribute to the distinct
retinoid processing pathways in cone photoreceptor cells [43].
The present study has identi¢ed RPE65 expression in some
transformed kidney cell lines but not in normal kidney tissues
or primary kidney cultures. This ¢nding suggests that trans-
formed cells may have an altered retinoid metabolic pathway
and may provide clues for elucidating the distinct retinoid
processing machinery in transformed kidney cells.
COS-1 and COS-7 cells are SV40-transformed African
green monkey kidney cell lines [44]. HEK293 cells are a hu-
man embryonic cell line transformed by adenovirus [45]. All
of these cells show a transformed growth and phenotypes. The
present study demonstrated that RPE65 is expressed in these
transformed kidney cells but not in normal kidney tissues or
cultures derived from normal kidney tissues. The mechanism
of activation of the RPE65 gene is unclear at this time. COS-
1, COS-7 and HEK293 cells were transformed by di¡erent
viruses and thus, the activated RPE65 expression cannot arise
from a speci¢c virus transformation. Because of the endoge-
nous expression of RPE65, these cell lines are not suitable
hosts for transfection and expression of exogenous RPE65.
The RPE65 mRNA was also detected in some types, but
not all of the renal tumors analyzed, suggesting that activa-
tion of the RPE65 gene transcription is dependent on the
tumor case. The expression of RPE65 in these renal tumors
remains to be con¢rmed at the protein level.
The RPE65 sequence isolated from the transformed kidney
cells is identical to that from the RPE. The sequence compar-
ison also con¢rmed that this protein is highly conserved dur-
ing evolution, as RPE65 from COS cells di¡ers from the hu-
man RPE65 only by two amino acids. Similarly, it does not
contain a hydrophobic transmembrane domain and thus, it is
unlikely to be a typical transmembrane protein. Sequence
conservation across species underscores its functional signi¢-
cance.
The physiological function of RPE65 protein is currently
uncertain, nevertheless, several lines of evidence have linked
it with retinoid metabolism or transport [10,11,41]. It was
demonstrated that RPE65 forms a complex with 11-cis retinol
dehydrogenase and may function as an enzyme complex in the
RPE [10]. In COS-7 cells, however, the mRNA of 11-cis ret-
inol dehydrogenase was not detected by RT-PCR (data not
shown), indicating that RPE65 does not complex with this
retinoid processing enzyme in COS cells. This ¢nding suggests
that the function of RPE65 in COS cells may not be necessar-
ily identical to that in the RPE. As retinoid processing and
transport have been found to be important for cell di¡eren-
tiation, embryogenesis and carcinogenesis [17^19,46], the acti-
vated expression of this retinoid processing protein in trans-
formed cells may contribute to the distinct retinoid
metabolism and signaling in transformed kidney cells. The
role of RPE65 expression in the retinoid metabolism in the
transformed cells remains to be studied.
Acknowledgements: The authors would like to thank Dr John C.
Saari at the University of Washington for kindly providing the mono-
clonal antibody to RPE65. This work was supported by Grants from
National Institutes of Health, EY122301 (J.-X. Ma) and EY04939
(R.K. Crouch) and an unrestricted departmental grant from Research
to Prevent Blindness.
References
[1] Bavik, C.-O., Levy, F., Hellman, U., Wernstedt, C. and Eriksson,
U. (1993) J. Biol. Chem. 268, 20540^20546.
[2] Hamel, C.P., Tsilou, E., Harris, E., Pfe¡er, B.A., Hooks, J.J.,
Detrick, B. and Redmond, T.M. (1993) J. Neurosci. Res. 34,
414^425.
[3] Bavik, C.-O., Busch, C. and Eriksson, U. (1992) J. Biol. Chem.
267, 23035^23042.
[4] Bernstein, P.S., Law, W. and Rando, R.R. (1987) Proc. Natl.
Acad. Sci. USA 84, 1849^1853.
[5] Blaner, W.S., Das, S.R., Gouras, P. and Flood, M.T. (1987)
J. Biol. Chem. 262, 53^58.
[6] Bridges, C.D. (1989) Vis. Res. 29, 1711^1717.
[7] Mata, N.L., Tsin, A.T. and Chambers, J.P. (1992) J. Biol. Chem.
267, 9794^9799.
[8] Okajima, T.-I., Wiggert, B., Chader, G. and Pepperberg, D.
(1994) J. Biol. Chem. 269, 21983^21989.
[9] Crouch, R.K., Chader, G.J., Wiggert, B. and Pepperberg, D.R.
(1996) Photochem. Photobiol. 64, 613^621.
[10] Simon, A., Hellman, U., Wernstedt, C. and Eriksson, U. (1995)
J. Biol. Chem. 270, 1107^1112.
[11] Redmond, T.M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen,
N., Goletz, P., Ma, J.-X., Crouch, R.K. and Pfeifer, K. (1998)
Nat. Genet. 20, 344^350.
[12] Marlhens, S., Bareil, C., Gri¡oin, J.-M., Zrenner, E., Amalric, P.,
Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T.M., Arnaud, B.,
Claustres, M. and Hamel, C.P. (1997) Nat. Genet. 17, 139^141.
[13] Gu, S.-M., Thompson, D.A., Srikumari, C.R.S., Lorenz, B.,
Finckh, U., Nicoletti, A., Murthy, K.R., Rathmann, M., Kuma-
ramanickavel, G., Denton, M.J. and Gal, A. (1997) Nat. Genet.
17, 194^197.
[14] Morimura, H., Fishman, G.A., Grover, S.A., Fulton, A.B., Ber-
son, E.L. and Dryja, T.P. (1998) Proc. Natl. Acad. Sci. USA 95,
3088^3093.
[15] Argiles, A., Kraft, N.E., Hutchinson, P., Senes-Ferrari, S. and
Atkins, R.C. (1989) Kidney Int. 36, 954^959.
[16] Argiles, A., Ootaka, T., Hill, P.A., Nikolic-Paterson, D.J.,
Hutchinson, P., Kraft, N.E. and Atkins, R.C. (1994) Kidney
Int. 45, 23^31.
[17] De Luca, L.M. (1991) FASEB J. 5, 2924^2933.
[18] Pijnappel, W.W.M., Hendriks, H.F.J. and Durston, A.J. (1996)
Eur. J. Clin. Nutr. 50, S29^S31.
[19] Durston, A.J., van der Wees, J., Pijnappel, W.W.M., Schilthuis,
J.G. and Godsave, S.F. (1997) Cell. Mol. Life Sci. 53, 339^349.
[20] Haussler, M.R., Donaldson, C.A., Kelly, M.A., Mangelsdorf,
D.J., Bowden, G.T., Meinke, W.J., Meyskens, F.L. and Sidell,
N. (1984) Biochim. Biochem. Acta 803, 54^62.
[21] Pasquali, D., Bellastella, A., Valente, A., Botti, G., Capasso, I.,
del Vecchio, S., Salvatore, M., Colantuoni, V. and Sinisi, A.A.
(1997) Eur. J. Endocrinol. 137, 410^414.
[22] Xu, X.C., Sneige, N., Liu, X., Nandagiri, R., Lee, J.J., Lukmanji,
F., Hortobagyi, G., Lippman, S.M., Dhingra, K. and Lotan, R.
(1997) Cancer Res. 57, 4992^4996.
[23] Xu, X.C., Sozzi, G., Lee, J.S., Lee, J.J., Pastorino, U., Pilotti, S.,
Kurie, J.M., Hong, W.K. and Lotan, R. (1997) J. Natl. Cancer
Inst. 89, 624^629.
[24] Li, Y., Dawson, M.I., Agadir, A., Lee, M.O., Jong, L., Hobbs,
P.D. and Zhang, X.K. (1998) Int. J. Cancer 75, 88^95.
[25] Bichler, E., Daxenbichler, G. and Marth, C. (1983) Oncology 40,
336^339.
[26] Bhat, P.V., Poissant, L., Falardeau, P. and Lacroix, A. (1988)
Biochem. Cell Biol. 66, 735^740.
FEBS 22065 7-6-99
J. Ma et al./FEBS Letters 452 (1999) 199^204 203
[27] Napoli, J.L. and Race, K.R. (1987) Arch. Biochem. Biosphys.
256, 95^101.
[28] Napoli, J.L. (1996) Clin. Immunol. Immunopathol. 80, S52^S62.
[29] Siegenthaler, G. (1996) Horm. Res. 45, 122^127.
[30] Taub, M. (1989) J. Cell. Physiol. 141, 24^32.
[31] Humes, H.D. and Cleslinski, D.A. (1992) Exp. Cell Res. 201, 8^
15.
[32] Sugawara, A., Sanno, N., Takahashi, N., Osamura, Y. and Abe,
K. (1997) Endocrinology 138, 3175^3180.
[33] Blackburn, J.G., Hazen-Martin, D.J., Detrisac, C.J. and Sens,
D.A. (1988) Kidney Int. 33, 508^516.
[34] Hazen-Martin, D.J., Chao, C.C., Wang, I.Y., Sens, D.A., Gar-
vin, A.J. and Wang, A.C. (1993) Pediatr. Pathol. 13, 37^52.
[35] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular
Cloning: A Laboratory Manual. Cold Spring Harbor Labora-
tory, Cold Spring Harbor, New York.
[36] Chomczynski, P. and Sacchi, N. (1997) Anal. Biol. Chem. 162,
156^159.
[37] Chen, N., Ma, J.-X., Corson, D.W., Hazard, E.S. and Crouch,
C.R. (1996) Invest. Opthalmol. Vis. Sci. 37, 1907^1913.
[38] Nicoletti, A., Wong, D.J., Kawase, K., Gibson, L.H., Yang-
Feng, T.L., Richards, J.E. and Thompson, D.A. (1995) Hum.
Mol. Genet. 4, 641^649.
[39] Kozak, M. (1989) J. Cell Biol. 108, 229^241.
[40] Bavik, C.-O., Eriksson, U., Allen, R. and Peterson, P.A. (1991)
J. Biol. Chem. 266, 14978^14985.
[41] Hamel, C.P., Tsilou, E., Harris, E., Pfe¡er, B.A., Hooks, J.J.,
Detrick, B. and Redmond, T.M. (1993) J. Biol. Chem. 268,
15751^15757.
[42] Bavik, C., Ward, S.J. and Ong, D.E. (1997) Mech. Dev. 69, 155^
167.
[43] Ma, J.-X., Xu, L., Lockman, D.K., Redmond, T.M. and Crouch,
R.K. (1998) Biochim. Biochem. Acta 1443, 255^261.
[44] Asano, M., Iwakura, Y. and Kawade, Y. (1985) Nucleic Acids
Res. 13, 8537^8586.
[45] Graham, F.L., Smiley, J., Russell, W.C. and Nairn, R. (1977)
J. Gen. Virol. 36, 59^74.
[46] De Luca, L.M. (1985) Med. Oncol. Tumor Pharmacol. 2, 175^
180.
FEBS 22065 7-6-99
J. Ma et al./FEBS Letters 452 (1999) 199^204204
